Free Access
Issue
Med Sci (Paris)
Volume 27, Number 10, Octobre 2011
Page(s) 817 - 819
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20112710008
Published online 21 October 2011
  1. Robert C, Mateus C. Anticorps anti–CTLA 4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Delevoye C, Giordano F, van Niel G, Raposo G. La biogenèse des mélanosomes : l’échiquier de la pigmentation. Med Sci (Paris) 2011 ; 27 : 153–162. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. GalmicheA, Ezzoukhry Z. Régulation de la survie cellulaire par les kinases de la famille RAF. Med Sci (Paris) 2010 ; 26 : 729–733. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Dalle S, Martin-Denavit T, Thomas L. Hypervariabilité génotypique des mélanomes : un défi thérapeutique. Med Sci (Paris) 2006 ; 22 : 178–182. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Bertolotto C, Busca R, Ballotti R, Ortonne JP. L’AMP cyclique est un régulateur de la pigmentation de la peau. Med Sci (Paris) 2001 ; 17 : 177–85. [CrossRef] [Google Scholar]
  6. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009 ; 69 : 3241–3244. [CrossRef] [PubMed] [Google Scholar]
  7. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 ; 363 : 809–819. [CrossRef] [PubMed] [Google Scholar]
  8. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011 ; 19 : 11–15. [CrossRef] [PubMed] [Google Scholar]
  9. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006 ; 66 : 9483–9491. [CrossRef] [PubMed] [Google Scholar]
  10. Marquette A, Andre J, Bagot M, et al. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 2011 ; 18 : 584–591. [Google Scholar]
  11. Cox AD, Der CJ. The raf inhibitor paradox: unexpected consequences of targeted drugs. Cancer Cell 2010 ; 17 : 221–223. [CrossRef] [PubMed] [Google Scholar]
  12. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006 ; 147 ( suppl 1) : S252–S257. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.